Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Imlifidase administered in the 20-HMedIdeS-19 (PAES) study

Phase 3

HHansa Biopharma AB

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Long Term Efficacy and SafetyActive, not recruiting

Long Term Efficacy and SafetyPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q2 2030

Phase 3Active, not recruiting

Long Term Efficacy and Safety

NCT05937750

Clinical

Trials by Indication[1]

Long Term Efficacy and Safety1 trial

A Prospective, Post-authorisation Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation, Including a Non-comparative Concurrent Reference Cohort

Active, not recruiting·HHansa Biopharma AB·Phase 3·NCT05937750·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Imlifidase administered in the 20-HMedIdeS-19 (PAES) study. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Imlifidase administered in the 20-HMedIdeS-19 (PAES) study. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Hansa Biopharma AB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: HHansa Biopharma AB

Related News